NCT07101614尚未招募2 期
An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 125
- 主要终点
- Pathologic complete response (pCR) rate
研究概览
简要总结
The objective of this study is to evaluate the efficacy and safety of chemotherapy plus toripalimab, with or without JS004,as neoadjuvant therapy for patients with triple-negative breast cancer (TNBC). TNBC patients were randomly assigned in a 2:2:1 ratio to receive either JS004 plus toripalimab plus chemotherapy, toripalimab plus chemotherapy, or chemotherapy alone.Surgery will be performed within 5 weeks after the last dose of neoadjuvant treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up visits.
- •Age ≥ 18 years.
- •ECOG score ≤
- •Newly diagnosed, non-metastatic breast cancer of stage II-III, confirmed by histopathology or cytopathology (T1c-2 cN1-2 (≥2cm) or T3-4 cN0-2).
- •Pathologically confirmed hormone receptor-negative (ER and PR negative) and HER2-negative advanced breast cancer. In cases of multiple pathological results, the definition of triple-negative breast cancer is based on the final molecular subtype result from the last biopsy pathology. (ER negativity: immunohistochemical staining in <1% of tumor cells; PR negativity: immunohistochemical staining in <1% of tumor cells; HER2 negativity: immunohistochemical score of 0, 1+, or FISH/CISH negative).
- •Have at least one measurable lesion according to the RECIST v1.1 criteria.
- •Functional levels of vital organs must meet the following requirements (without any corrective treatment with blood components or cytokine growth factors within 14 days before the first dose):
- •Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, hemoglobin ≥ 90 g/L.
- •Liver and kidney function: Albumin level ≥ 3.0 g/dL, total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, urea nitrogen and serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min (calculated according to the Cockcroft-Gault formula).
- •Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- •Echocardiography (ECHO) showing left ventricular ejection fraction (LVEF) ≥ 50%.
- •QTcF ≤ 470 msec.
- •Within 7 days before the first dose, women of reproductive potential must have a negative serum pregnancy test and agree to use effective contraceptive measures during the study drug administration and for 6 months after the last dose. For this protocol, women of reproductive potential are defined as sexually mature women who: 1) have not undergone hysterectomy or bilateral oophorectomy, and 2) have not experienced spontaneous menstruation cessation for a continuous period of 24 months (amenorrhea following cancer treatment does not exclude fertility) (i.e., menstruation has occurred at any time within the previous 24 consecutive months). For male patients with female partners of reproductive potential, they must agree to use effective contraceptive measures during the study drug administration and for 6 months after the last dose.
- •Voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with visits and study-related procedures.
排除标准
- •Prior exposure to drugs targeting the same therapeutic target as the study treatment drug planned for administration.
- •Radiotherapy, chemotherapy, surgery, or other targeted immunotherapy for triple-negative breast cancer before enrollment.
- •Uncontrolled central nervous system metastases (symptomatic or requiring glucocorticoids or mannitol for symptom control).
- •Inflammatory breast cancer, bilateral breast cancer, or occult breast cancer.
- •History of clinically significant or uncontrolled cardiac disease within 6 months before the first dose, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmias.
- •Presence of severe concomitant diseases that, in the investigator's judgment, pose a significant risk to the patient's safety or ability to complete the study (including but not limited to severe hypertension not controlled by medication, severe diabetes, active infections, etc.).
- •Malignancy within 5 years before the first dose (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ).
- •Active autoimmune diseases requiring systemic treatment within 2 years before the first dose, except for vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy.
- •Receipt of live or attenuated vaccines within 4 weeks before the first dose of the study drug.
- •Known or suspected interstitial pneumonia. Presence of other moderate to severe respiratory diseases within 3 months before the first dose that may interfere with the detection or management of drug-related lung toxicity, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia/bronchiolitis obliterans, pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease (COPD), obstructive/restrictive lung diseases, etc.; as well as any autoimmune, connective tissue, or inflammatory diseases affecting the lungs, such as rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc., or prior total lung resection surgery.
- •Known history of human immunodeficiency virus (HIV) infection.
- •Known history of hepatitis B or active hepatitis C virus infection.
- •Prior allergy to any component or excipient of the study drug planned for administration.
- •Other conditions deemed unsuitable for participation in the study by the investigator.
研究组 & 干预措施
JS004+Toripalimab+chemotherapy
Experimental
干预措施: JS004 in combination with toripalimab and chemotherapy (Drug)
Toripalimab+chemotherapy
Experimental
干预措施: Toripalimab and chemotherapy (Drug)
chemotherapy
Other
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Pathologic complete response (pCR) rate
时间窗: Up to 30 months
PCR rate is defined as the proportion of participants who have achieved pathologic complete response (on routine hematoxylin and eosin staining, no tumor cell can be found in tumor bed or lymph node) in all participants.
次要结局
- Event-free Survival (EFS)(Up to 30 months)
- Objective response rate (ORR)(Up to 30 months)
- Breast pathologic complete response (bpCR)(Up to 30 months)
- Residual Cancer Burden (RCB) 0-1(Up to 30 months)
- Incidence of adverse event(Up to 30 months)
研究者
Caigang Liu
Shengjing Hospital
Shengjing Hospital
相似试验
招募中
3 期
Toripalimab for Local-regional Recurrent Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaNCT04376866Cancer Hospital of Guangxi Medical University204
尚未招募
2 期
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Non Small Cell Lung Cancer RecurrentNCT05842018Tianjin Medical University Cancer Institute and Hospital30
进行中（未招募）
3 期
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04907370Sun Yat-sen University532
招募中
3 期
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)Hodgkin LymphomaNCT06170489Shanghai Junshi Bioscience Co., Ltd.185
尚未招募
2 期
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerTNBC - Triple-Negative Breast CancerBreast CancerNCT05491694The First Affiliated Hospital with Nanjing Medical University20